HEALTH

Bausch + Lomb introduces consumer-preferred cap design

BY Michael Johnsen

CHICAGO — Bausch + Lomb recently introduced a new consumer-preferred cap design across its Renu multi-purpose contact lens solution brand. 

The design and overseal snap provides for an added ease of use, the company stated.  

The Renu brand in July celebrated 25 years on the shelf. First introduced in 1987, the brand helped revolutionize the contact lens solution category as a daily, single-bottle contact lens care regimen.

"We are proud that Bausch + Lomb modernized the way people care for their eyes by introducing an innovative brand that not only made contact lenses more convenient and accessible but has remained a leading personal care product for more than a quarter of a century," Kimberly Gobel, marketing director of lens care, Bausch + Lomb North American Vision Care, stated this summer. 

The Renu brand multi-purpose solutions are available in two formats — Renu Fresh multi-purpose solution and Renu Sensitive multi-purpose solution.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

Westport Pharmaceuticals launches Zephrex-D, a tamper-resistant PSE formulation

BY Michael Johnsen

ST. LOUIS – Westport Pharmaceuticals on Tuesday launched Zephrex-D, a tamper-resistant pseudoephedrine-based decongestant that now is available in retail stores throughout the St. Louis region and the state of Missouri. 

The unique formulation of Zephrex-D provides decongestant relief for consumers while protecting against the illicit manufacture of methamphetamine. “The arrival of Zephrex-D is an integral part of a comprehensive solution to help end meth labs and meth-related crime in our local communities, throughout Missouri and ultimately, across our country," stated Paul Hemings, VP and general manager for Westport. 

Because it is a pseudoephedrine-based product, it still will be available behind the pharmacy counter as regulated by the Combat Methamphetamine Epidemic Act of 2005. Some local ordinances require prescriptions to purchase pseudoephedrine products, but Zephrex-D has been exempted from the prescription requirement in several instances, the company reported. 

Westport Pharmaceuticals has applied to the federal government for an exemption from the restrictions created by CMEA, the company reported on its website Zephrex-d.com/. "This exemption would enable retailers to place Zephrex-D back in their OTC sections, return direct consumer access to pseudoephedrine, save time and administrative costs for pharmacists, all while helping to reduce methamphetamine-related crime. Consumers win, retailers win and ‘meth cooks’ lose."

Zephrex-D is made using Tarex, Highland Pharmaceuticals’ patented technology that blocks the meth-making process while still providing full congestion relief for patients. "Our technology frustrates the most well-known methods of drug abuse, i.e. crushing for inhalation and injection, and extraction for concentrating for injection," Highland Pharmaceuticals stated in explaining the process. "Highland Pharmaceuticals can deliver both opioid-based analgesics and pseudoephedrine in GRAS formulation, thereby providing a new and unconventional approach to combat the issue of drug abuse."

According to Highland, when pseudoephedrine is delivered in the Tarex format, the standard extraction process is derailed, making the attempt to extract the active ingredient from the tablet unsuccessful. Accordingly, the resulting output cannot be used in subsequent steps to make methamphetamine. 

Any retailer inquiries regarding Zephrex-D should be directed to Advantage Consumer Healthcare, Westport’s national sales and marketing partner. Either Greg Bradley or Clark Brown can be reached at 412-706-5440, or via email at www.advantagechc.com.  

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

Pfizer closes deal, sells nutrition business to Nestlé for $11.9 billion

BY Michael Johnsen

NEW YORK — Pfizer on Friday announced that it has completed the sale of its nutrition business to Nestlé for $11.9 billion in cash, following the conclusion of the required regulatory process in most markets. In certain countries where completion will be delayed due to ongoing regulatory review, Pfizer will continue to operate the business on an interim basis.

Pfizer Nutrition, formerly Wyeth Nutrition, supplies nutritional products that are scientifically designed to help meet the needs of infants and young children, as well as pregnant and lactating mothers. The company’s brands — including infant formulas Promil, Progress and Promise Gold, and maternal supplement Materna — are available across more than 60 countries.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES